Therapy of Alzheimer's disease: Current status and future development;Therapie der Alzheimer demenz: Derzeitiger stand und zukünftige entwicklung

Neuropsychiatrie

Volumn 22, Issue 3, 2008, Pages 153-171

  Schmidt, Reinhold ^a   Neff, Frauke ^b   Lampl, Christian ^c   Benke, Thomas ^d   Anditsch, Martina ^e   Bancher, Christian ^f   Dal Bianco, Peter ^g   Reisecker, Franz ^h   Marksteiner, Josef ⁱ   Rainer, Michael ^e   Kapeller, Peter ^j   Dodel, Richard ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Konventspital Barmherzige Bruder Linz

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e DANUBE HOSPITAL   (Austria)

^f Abteilung für Neurologie   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

ⁱ GENERAL HOSPITAL KLAGENFURT   (Austria)

^j Landeskrankenhaus Villach

more..

Author keywords

Alzheimer dementia; Cholinesterase inhibitors; Compliance; Drug interactions; Once daily use; Therapeutic strategies

Indexed keywords

ACC 001; AD 01; ALPHA SECRETASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ATORVASTATIN; BAPENEUZUMAB; BAPINEUZUMAB; BETA SECRETASE; CAD 106; CHOLINESTERASE INHIBITOR; CTS 21166; DONEPEZIL; E 2012; ELND 005; FLURBIPROFEN; GALANTAMINE; GAMMA SECRETASE; GLITAZONE DERIVATIVE; GSI 953; HOMOTAURINE; IMMUNOGLOBULINE; LY 2062430; MEMANTINE; MK 0752; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NICASTRIN; PAZ 417; PBT 2; PF 04360365; PF 04494700; PIOGLITAZONE; PITAVASTATIN; PLACEBO; PPI 1109; PRAVASTATIN; QS 21; R 1450; RIVASTIGMINE; ROSIGLITAZONE; SCYLLO INOSITOL; SIMVASTATIN; TARENFLURBIL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ENZYME INHIBITION; HUMAN; PATIENT COMPLIANCE; PROTEIN AGGREGATION; REVIEW;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; DRUG INTERACTIONS; DRUG UTILIZATION; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOTHERAPY; MEMANTINE; NEUROFIBRILLARY TANGLES; NOOTROPIC AGENTS; PATIENT COMPLIANCE; SENILE PLAQUES;

EID: 55549131908     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.
2. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1-26.
3. Alf C, Bancher C, Benke T,Berek K, Bodner T, Croy A, et al. Konsensusstatement 'Demenz' der Österreichischen Alzheimer Gesellschaft - Update 2006. Neuropsychiatrie 20, 2006; 20: 221-31.
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;CD005593.
5. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007;120:388-97.
6. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003;2:539-47.
7. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21:1317-1327
8. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm A, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-65.
9. Black SE, Doody R, Li H McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459-69
10. Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol 2003;2:503-5.
11. McShane R, Areosa SA, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;CD003154.
12. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005;CD003154.
13. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6:501-12.
14. Bentué-Ferrer D, Tribut O, Polard E, Allain H Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17(13):947-63
15. Waldemar G, Phung TT, Burns A Georges J, Hansen FR, Iliffe S, Marking C, Rikkert MO, Selmes J, Stoppe G, Sartorius N. Access to diagnostic evaluation and treatment for dementia in Europe. International Journal of Geriatric Psychiatry 2007; 22, 47-54
16. Bickel, H. Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Zeitschrift für Gerontologie und Geriatrie 2001; 34, 108-115
17. Becker M, Andel R, Rohrer L, Banks SM. The effect of cholinesterase inhibitors on risk of nursing home placement among medicaid beneficiaries with dementia. Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3):147-52
18. Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics. 2005;23(2):193-206
19. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P; AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004 Jun 26;363(9427):2105-15
20. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V; Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. 2004 Aug 24;63(4):644-50
21. Gillette-Guyonnet S, Andrieu S, Cortes F, Nourhashemi F, Cantet C, Ousset PJ, Reynish E, Grandjean H, Vellas B. Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors J Gerontol A Biol Sci Med Sci. 2006 May;61(5):516-20
22. Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings J Manag Care Pharm. 2005 Apr;11(3):231-51
23. Roe CM, Anderseon MJ, Spivack B. How many patients complete an adequate trial of donepezil ? Alzheimer Dis Assoc Disorder 2002; 16: 49-51
24. Singh G, Thomas SK, Arcona S, Lingala V, Mithal A. Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J Am Geriatr Soc. 2005 Jul;53(7):1269-70
25. Osterberg L, Blaschke T Adherence to medication N Engl J Med. 2005 Aug 4;353(5):487-97
26. Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis CMAJ. 2003 Sep 16;169(6):557-64
27. Suh DC, Thomas SK, Valiyeva E, Alcona S, Vo L. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging. 2005;22(8):695-707
28. Winblad B, Grossberg G, Frölich L. Farlow M, Zechner S, Nagel J, Lane R. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007 Jul 24;69(4 Suppl 1):S14-22.
29. Hardy J.: Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 2006; 3,71-73
30. Mandelkow E., von Bergen M., Biernat J., Mandelkow E.M.: Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol 2007; 17,83-90.
31. Cheng I.H., Scearce-Levie K., Legleiter J., Palop J.J., Gerstein H., Bien-Ly N., Puolivali J., Lesne S., Ashe K.H., Muchowski P.J., Mucke L.: Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. The Journal of biological chemistry 282,2007; 23818-23828.
32. Lesne S., Koh M.T., Kotilinek L., Rayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H.: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440,352-357.
33. Dewachter I., Van Leuven F.: Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol 2002; 1: 409-416.
34. Evin G., Sernee M.F. Masters C.L.: Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 2006; 20:351-372.
35. Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., Johnson R.S., Castner B.J., Cerretti D.P., Black R.A.: Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. The Journal of biological chemistry 1998; 273: 27765-27777.
36. Fahrenholz F., Postina R.: Alpha-secretase activation - an approach to Alzheimer's disease therapy. Neurodegener Dis 2006; 3: 255-261.
37. Bandyopadhyay S., Goldstein L.E., Lahiri D.K., Rogers J.T.: Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimers disease. Current Medicinal Chemistry 2007;14:2848-2864.
38. Wolf B.A., Wertkin A.M., Jolly Y.C., Yasuda R.P., Wolfe B.B., Konrad R.J., Manning D., Ravi S., Williamson J.R., Lee V.M.: Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. The Journal of Biological Chemistry 1995; 270: 4916-5022.
39. Roberds S.L., Anderson J., Basi G., Bienkowski M.J., Branstetter D.G., Chen K.S., Freedman S.B., Frigon N.L., Games D., Hu K., Johnson-Wood K., Kappenman K.E., Kawabe T.T., Kola I., Kuehn R., Lee M., Liu W., Motter R., Nichols N.F., Power M., Robertson D.W., Schenk D., Schoor M., Shopp G.M., Shuck M.E., Sinha S., Svensson K.A., Tatsuno G., Tintrup H., Wijsman J., Wright S., McConlogue L.: BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Human molecular genetics 2001;10:1317-1324.
40. Evin G., Kenche V.B.: BACE inhibitors as potential therapeutics for Alzheimer's disease. Recent Patents CNS Drug Discov 2007; 2,188-199.
41. Commentis Inc. Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer's Disease Therapy 2008.
42. Ohno M., Sametsky E.A., Younkin L.H., Oakley H., Younkin S.G., Citron M., Vassar R., Disterhoft J.F.: BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 2004; 41:27-33.
43. Wolfe M.S.: The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 2006;45: 7931-7939.
44. Nguyen J.T., Yamani A., Kiso Y.: Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer's disease: progress and problems. Curr Pharm Des 12,4295-312 (2006).
45. Olson R.E., Albright C.F.: Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem 2008; 8: 17-33.
46. Siemers E.R., Dean R.A., Friedrich S., Ferguson-Sells L., Gonzales C., Farlow M.R., May P.C.: Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007; 30: 317-325.
47. Tomita T.: At the frontline of Alzheimer's disease treatment: gamma-secretase inhibitor/modulator mechanism. Naunyn Schmiedebergs Arch Pharmacol 2007.
48. Weggen S., Rogers M., Eriksen J.: NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends in Pharmacological Sciences 2007; 28: 536-43.
49. Galasko D.R., Graff-Radford N., May S., Hendrix S., Cottrell B.A., Sagi S.A., Mather G., Laughlin M., Zavitz K.H., Swabb E., Golde T.E., Murphy M.P. Koo E.H.: Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 2007; 21: 292-299.
50. Myriad Pharmaceuticals. 2008 02.03.2008. Accessed 02.03.2008.
51. Schenk D., Barbour R., Dunn W., Gordon C., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P.: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177.
52. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Licberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T.: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919.
53. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W.: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-995.
54. Solomon B.: Antibody-mediated immunotherapy for Alzheimer's disease. Curr Opin Investig Drugs 2007;8': 519-524.
55. Dodel R.C., Hampel H., Du Y.: Immunotherapy for Alzheimer's disease. Lancet Neurol 2003; 2:215-220.
56. Schenk D.: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002; 3: 824-828.
57. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., Fisher Y., Owens T., Weiner H.L.: Abeta-indueed meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2006; 103: 5048-5053.
58. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M.: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64,1553-1562.
59. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., Costa-Jussa F.: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
60. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D.: Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005: 64,129-131.
61. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O.: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9:448-452.
62. Solomon B.: Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease. Drugs Today (Barc) 2007;43,333-342.
63. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., Janus C., Chishti M.A., Horne P., Westaway D., Fraser P.E., Mount H.T., Przybylski M., St George-Hyslop P.: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002; 8:1263-1269.
64. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M.: Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98:8850-8855.
65. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M.: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002; 5:452-457.
66. Kayed R., Head E., Sarsoza F., Saing T., Cotman C.W., Necula M., Margol L., Wu J., Breydo L., Thompson J.L., Rasool S., Gurlo T., Butler P., Glabe C.G.: Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2007;2:18.
67. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., Nitsch R.M.: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38:547-554.
68. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., Babikyan D., Kesslak P., Kieber-Emmons T., Cotman C.W., Agadjanyan M.G.: Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. International immunology 2003; 15: 505-514.
69. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., Koller M.: Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64:1563-1572.
70. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., Heneka M.T.: Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 2006; 103:443-448.
71. Dodel R., Du Y., Depboylu C., Hampel H., Frölich L., Haag A., Hemmeter U., Paulsen S., Teipel S., Brettschneider S., Spottke A., Nölker C., Möller H., Wei X., Farlow M., Sommer N.O., WH: Intravenous Immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry 2004; 75: 1472-1474.
72. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., Weksler M.E.: 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2008.
73. Baxter: Clinical trials of IVIG in the treatment of Alzheimer. http://www-baxtercom/about_baxter/news_room/news_releases/2007/ 08-28-07-ivightml 2007.
74. Gervais F., Paquette J., Morissette C., Krzywkowski P., Yu M., Azzi M., Lacombe D., Kong X., Aman A., Laurin J., Szarek W.A., Tremblay P.: Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007; 28:537-547.
75. Aisen P.S., Saumier D., Briand R., Laurin J., Gervais F., Tremblay P., Garceau D.: A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006; 67: 1757-1763.
76. Aisen P.S., Gauthier S., Vellas B., Briand R., Saumier D., Laurin J., Garceau D.: Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res 2007; 4: 473-478.
77. Popik P., Galoch Z., Janusz M., Lisowski J., Vetulani J.: Cognitive effects of Colostral-Val nonapeptide in aged rats. Behav Brain Res 2001; 118: 201-208.
78. Bilikiewicz A., Gaus W.: Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimers Dis 2004; 6: 17-26.
79. Sampson E., Jenagaratnam L., McShane R.: Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database Syst Rev,CD005380; 2008.
80. Masters C.: Alzheimer's disease: Aβ-amyloid as the principal molecular therapeutic and diagnostic target Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2007; 3,S91.
81. Townsend M., Cleary J.P., Mehta T., Hofmeister J., Lesne S., O'Hare E., Walsh D.M., Selkoe D.J.: Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 2006; 60,668-676.
82. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., van Duijn C.N., Van Broeckhoven C., Grobbee D.E.: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349:151-154.
83. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G.: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57:1439-1443.
84. Whitfield J.F.: Can statins put the brakes on Alzheimer's disease? Expert opinion on investigational drugs 2006; 15,1479-1485.
85. Ehehalt R., Keller P., Haass C., Thiele C., Simons K.: Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. The Journal of cell biology 2003; 160:113-123.
86. Reid P.C., Urano Y., Kodama T., Hamakubo T.: Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. Journal of cellular and molecular medicine 2007; 11: 383-392.
87. Parsons R.B., Farrant J.K., Price G.C., Subramaniam D., Austen B.M.: Regulation of the lipidation of beta-secretase by statins. Biochemical Society transactions 2007; 35: 577-582.
88. Abdulkarim Y., Hameed Z.: Is the LDL receptor involved in cortical amyloid protein clearance? Neurochemical research 2006; 31,839-847.
89. Arvanitakis Z., Schneider J.A., Wilson R.S., Bienias J.L., Kelly J.F., Evans D.A., Bennett D.A.: Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008; 70: 1795-1802.
90. Scott H.D., Laake K.: Statins for the prevention of Alzheimer's disease. Cochrane review and plain language summary. http://wwwcochraneorg/reviews/en/ ab003160html 2006.
91. National Institutes of Health. 2008 03. www.clinicaltrials.gov. National Instituts of Health, Accessed 2008 03.
92. Castrillo A., Tontonoz P.: Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annual review of cell and developmental biology 2004; 20: 455-480.
93. Jiang Q., Heneka M., Landreth G.E.: The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008; 22,1-14.
94. d'Abramo C., Massone S., Zmgg J.M., Pizzuti A., Marambaud P., Dalla Piccola B., Azzi A., Marinari U.M., Pronzato M.A., Ricciarelli R.: Role of peroxisome pioliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. The Biochemical journal 2005; 391:693-698.
95. Pedersen W.A., Flynn E.R.: Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiology of disease 2004; 17:500-506.
96. Hull M., Lieb K., Fiebich B.L.: Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Current medicinal chemistry 2002; 9,83-88.
97. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., Zvartau-Hind M.E., Hosford D.A., Roses A.D.: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006; 6: 246-254.
98. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.O., Kahn S.E., Keeling M.L., Craft S.: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13,950-958.
99. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc.Natl.Acad.Sci 1986; 83:4913-4917
100. Lindwall G, Cole RD. Phosphorylation affects the the ability of tau to promote microtubule assembly. J Biol Chem 1984; 259: 5301-5305
101. Khatoon S, Gundke-Iqbal I, Iqbal K. Levels of normal and abnormally phophorylated tau in different cellular and regional compartments of Alzheimer disease and control brains FEBS Lett 1994; 351: 80-84
102. Wang JZ, Grundke-Iqbal I, Iqbal K. Restoration of biological activity od Alzheimer abnormally phosophorylated tau by dephoshorylation with protein phosphatise-2A,-2B and -1. Brain Res Mol Brain Res 1996;38:200-208
103. Pei JJ, Gong CX, An WL, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K. Okaadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2,MEK1/2 and p70 S6, similar to that in Alzheimer's disease. Am J Pathol 2003; 163: 845-858
104. Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol 1998;8:425-427
105. Shahani N, Brandt R. Functions and malfunctions of the tau proteins. Cell Mol Life Sci 2002; 59: 1668-1680
106. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ Age-dependent emergence and progression of a tauopathy in transgeneic mice overexpressing the shortest tau isoform. Neuron 1999;24:751-762
107. Klafki H-W, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006; 129: 2840-2855
108. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A. 2005;102:6990-6995
109. Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol. 2007;152:959-979
110. Le Corre S, Klafki HW, Plesnila N, Hübinger G, Obermeier A, Sahagún H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, Roder HM. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A. 2006;103:9673-8
111. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004;566:261-269
112. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, Sultana R. Pin1 in Alzheimer's disease J Neurochem. 2006;98:1697-1706
113. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH Tau suppression in a neurodegenerative mouse model improves memory function Science. 2005 ;309:476-481
114. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs J Biol Chem. 2006 ;281:1205-1214
115. Khlistunova I, Pickhardt M, Biernat J, Wang Y, Mandelkow EM. Mandelkow E. Inhibition of tau aggregation in cell models of tauopathy Curr Alzheimer Res. 2007; 5)544-546